Pharma, Medical & Biotech
Virtual Event: Nordic Market Outlook - Impact of Covid-19 and challenges for Q2 2020 and beyond
Watch Mergermarket’s Virtual Event on the Nordic market outlook and the impact of Covid-19 here.

Webinar: UK M&A set to fall as firms react to coronvirus pandemic
Watch Mergermarket's webinar on UK M&A and the impact of COVID-19 here.
Macro headwinds sink pharma multiples but megadeals persist
The Pharma, Medical and Biotech (PMB) sector has seen a significant rise in the value of deals in 2019, despite a slowdown in M&A activity
Dealcast: Allergan reaction
The European Commission (EC) is reviewing AbbVie’s [NYSE:ABBV] proposed acquisition of Botox producer Allergan [NYSE:AGN]. The merging parties have already pledged to divest such products as brazikumab, a drug under development for ulcerative colitis and Crohn’s disease, and Zenpep (pancrelipase), which treats a pancreatic disorder, but the EC may want more changes if it is to approve the deal. Dealreporter’s Pablo Mayo Cerqueiro and Mergermarket’s Mintoi Chessa-Florea joined us to discuss how the EC’s review is likely to go.
Lundbeck ready to make acquisitions
Danish pharmaceutical company Lundbeck [CPH: LUN] is poised for a run of M&A to replenish its drug pipeline. We caught up with our Nordics reporter, Karoliina Liimatainen, who spoke recently with the company's chief executive, Deborah Dunsire, and has more on the company's plans for growth.
Portuguese dealmakers optimistic about M&A amid robust economic performance
- Improving GDP prompts deal confidence
- 2018 M&A transactions highest on record
- Deals expected in TMT, energy and health sectors

DACH Trendspotter: Macroeconomic tensions unlikely to jilt German dealflow
- Positive lending environment opens doors for deals
- Protectionist measures could threaten larger transactions
- IPO market upbeat after successful flurry in 1H18

Anya Cummins on the challenges and opportunities facing Irish M&A
A year on from the last time we sat down with Anya Cummins, Partner and Head of M&A at Deloitte we wanted to see if there is any more certainty around Brexit since Article 50 was triggered. We were also keen to find out what the deal drivers are for Irish M&A and PE investments in the next 12 months.

3 tips to raising capital in the Irish market
Brian Crowley, CEO and Founder at TTM Healthcare shares his tips to raising capital in Ireland and what its like working with private equity backing.

German M&A Deal Drivers for 2016
A panel of bankers and corporates sat down at the Mergermaket Germany Forum to discuss the outlook for their sectors and companies and the M&A drivers that will play in delivering growth. Here's what they said...
Irish outbound M&A hits the heights in 2014
Irish dealmakers are looking overseas for deals as business look for growth beyond borders.
The three sectors driving the US M&A revival
US M&A has hit new heights in 2014. This has been driven by three sectors, which are forging ahead of other industries.
No more items to load
Load moreAn error occurred trying to play the stream. Please reload the page and try again.
Close